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PaOJF,O, PaCO, Timeto 3 h T h e  to 
post aíter rewarm drains dlschage 
Control (n=14) 243 (36) 6.3 (0.7) 3.5 (0.79) 218 (50) 8.4 (0.5) 
RemifentanIl (n=13) 292 (34) 6.1 (0.6) 2.1 (0.2) 241 (54) 6.6 (0.26) 
D 0.33 0.41 0.11 0.76 0.015 
extubatlon (h) loss (days) bypass----  
Table: Results 
[SE]) for oxygen exchange (ratio of partial pressure of 
oxygen in arterial blood to inspired oxygen, PaO,/F,O,), 
arterial carbon dioxide tension (PaCO,), time to rewarming, 
and early drains loss. All these data were similar between 
groups as were the preoperative cardiovascular status, 
duration of surgery, and ischaemic period during bypass. 
The time to extubation was shorter (p=0*025) in patients 
anaesthetised with the remifentanil-based TIVA method, On 
average these patients were extubated 2.5 hours earlier than 
patients given inhalational anaesthetic with fentanyl. The 
range in times to extubation was 3-7 hours in this TIVA 
group and 33-11 hours in the other patients. One of us 
(T S) suggested that earlier extubation was also associated 
with an earlier discharge from hospital. This clinical 
impression was confirmed in this small group of patients. 
These observations are difficult to explain. However, these 
data show that it is possible to achieve early postoperative 
extubation with TIVA alone. The data also suggest that 
variations in anaesthetic technique affects subsequent rate of 
recovery. 
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Efficacy of SPf66 vaccine against 
Plasmodium faleiparum malaria in children 
Sir-Alonso and colleagues (Oct 29, p 1175) report a 
decrease id the frequency of clinical malaria among 
Tanzanian children who had received the SPf66 malaria 
vaccine developed by Pattaroyo. These results were obtained 
in an area where malaria transmission rate is one of the 
highest in the wwld, with about 300 infective bites per 
person each year. It therefore seems surprising that such a 
small number of malaria attacks-0.35 annual incidence 
rate-was recorded in the placebo group. Malarial morbidity 
was measured by passive case detection at the dispensary. In 
a subgroup consisting of about a third of children, active 
case detection was also done by weekly home visits. As the 
investigators point out, these methods can detect only a 
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Figure: Annual incidence of malaria attacks by age, Dielmo 
(Senegal), June, 1990, to May, 1992 
the children. In one village in the Congo where malaria 
transmission was 246 infective bites per person per year,' we 
rborded a minimum of 3 attacks per year among children 
aged 5-6 years.2 Since 1990 in Senegal, we have been 
monitoring the population in a village where Plasniodiuni 
faZcipamnz transmission is permanent, and varies yearly from 
101 to 273 infective bites per person." Each child is visited 
daily at home, his temperature is recorded three times a 
week, and a medical team is on call day and night in the 
research station in the village to diagnose and treat every 
pathological episode.3~~ The figure shows that. the frequency 
of malaria attacks among children from O to 6 years varies 
according to age from 2.6 to 6.1 attacks per year, which is an 
average of 4.1 attacks per year in children of the same age as 
the Tanzanian group. The diagnostic criteria used were 
practically identical for the three s ~ r v e y s . ~ ~ ~  The Tanzanian 
vaccine trial may therefore have only detected 1 in 8-12 
cases of actual malaria, dependent on the subgroup. The 
reason for this is the very short duration (usually one or two 
days eyen without treatment) of ,most clihical malaria 
episodes in children exposed to intense perennial 
transmission, and the erratic nature of peaks of fever during 
these episodes. 
We believe that the malaria attacks detected by Alonso 
and colleagues include most of the potentially severe cases, 
but only a small percentage of other cases. The decrease in 
the frequency of episodes detected in vaccinated children 
could result from a decrease in intensity of the symptoms 
rather than the number of attacks, and it is possible that the 
vaccine reduces malaria mortality in a higher proportion 
than the 31% recorded for the clinical episodes that were 
detected. The results of the Tanzanian trial jusrify further 
trials on a larger scale, to establish the impact of SPf66 on 
malaria mortality in highly endemic areas; such trials should 
take into account the potential effect of the vaccine on the 
intensity of symptoms. 
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SIR-Trape and Rogier rightly point out that in the 
Tanzanian SPf66 trial the reported annual incidence of 
clinical episodes was lower than the number of episodes 
expected in an area of such high malaria transmission. There 
are probably several reasons for this. 
The highest risk of clinical malaria in the Kilombero 
population occurs around the first birthday. In areas like this 
one, where transmission is so intense, the frequency of 
clinical. malaria declines very rapidly with age. Indeed 
1-year-old children have twice the risk of 2-year-olds. For 
regulatory reasons we could not vaccinate children less than 
1 year of age. Consequently, most of the time, at risk refers 
to children who were older (up to 7 years by the end of the 
trial) and had much lower risk of symptomatic episodes. 
Furthermore, the study cohorts were ageing as the trial 
progressed and the risk of malaria therefore decreased. At 
the same time, primary data analysis depended on passive 
case detection at the village dispensary. Even though the 
dispensary staff and supplies were re-enforced during the 
study period, and free medical services were offered around 
the clock for the entire duration of the trial, it is quite likely 
that children with mild, short-duration, and self-limited 
. episodes did not attend the dispensary for consultation, and 
were therefore not reported. The dispersed structure of the 
village could have also contributed to the low recorded 
frequency (mean distance from the dispensary 1.9 km, 
interquartile range 0.94.8). The recorded frequency was 
higher in children who lived nearest the dispensary, 
suggesting that reporting rates were lower from more remote 
parts of the village. 
Moreover, symptomless infections occur at a high 
frequency in the Tanzanian study area, and this complicates 
the analysis of any trial of interventions against malaria 
morbidity. Children with fevers of non-malarial aetiology 
can have corícurrent symptomless parasitaemia, and 
therefore we can never be entirely sure that the parasites are 
the cause of the fever; this is especially so when sick children 
are not necessarily examined at either the peak of fever or 
peak parasitaemia of the episode. In the Kilombero vaccine 
trial, many such episodes would not, at the time of sampling, 
have satisfied our primary case definition, which included 
only episodes presenting with an axillary temperature 
of 375°C or more and a parasite density greater than 
20 0001pL. The risk of fever does, however, increase with 
the density of parasitaemia. We have lately used this 
observation to show how the sensitivity and specificity of 
difFerent parasitaemia cutoffs can be determined.1s2 The case 
definition used for the primary analysis was established 
before the randomisation code was broken, with the data 
obtained during the 6 months of follow-up between the first 
and third dose. A definition with a high specificity was 
chosen to avoid the dilution of the vaccine effect by 
inclusion of fever cases with non-malarial aetiology. 
All these considerations combined with the known time- 
dependent variability on the frequency of clinical malaria as 
indicated by the.reducdon over time in the age-standardised __ 
the episodes detected include most of the potentially severe 
cases. We also agree that the vaccine-related reduction in the 
number of episodes recorded could be due to a decrease in 
the intensity of symptoms rather than number of the 
attacks-ie, shifting the spectrum of clinical severity towards 
the more benign presentations. If this is so, the vaccine 
might have a substantial impact on mortality that needs to 
be documented. 
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Regional variations in medium-chain acyl-COA 
dehydrogenase deficiency 
SIR-Medium-chain acyl-COA dehydrogenase (MCAD) 
deficiency is an autosomal recessive disorder of 
mitochondrial fatty acid oxidation. About 90% of patients 
are homozygous for the same mutation (G985). Affected 
individuals are at risk of metabolic decompensation, 
especially during infancy, and may present with 
hypoglycaemia, encephalopathy, hepatomegaly, and sudden 
death or near-miss episodes, though some remain symptom- 
free.' Preliminary studies from the West Midl&dG and 
Trene regions of the UK found heterozygosity for G985 in 
12 of 479 and 6 of 410 babies, respectively, suggesting that 
in these areas 1 in 10000 individuals have MCAD 
relatively common disorder, and one that may be widely 
underdiagnosed.' However, the statistical limitations of these 
small surveys left unanswered many questions about the 
impact of the disease and the case for routine neonatal 
screening. We have now examined over 10 O00 samples and 
have compared the predicted frequencies of MCAD 
deficiency with the rates of diagnosis in the two regions. 
The West Midlands study covered the Herefordshire, 
Shropshire, and North and South Worcestershire health 
districts. In Trent eleven of the thirteen districts 
participated. Dried blood surplus to routine screening was 
tested for G985 by polymerase chain amplification and 
allele-specific hybridisation? All samples in the heterozygous 
range were then examined by SyI  restriction enzyme 
digestion followed by gel electrophoresis. (Details of assay 
performance will be reported elsewhere but if there is any 
bias it will be to underestimate heterozygote frequency.) The 
results (table) confirm previous indications2j3 that gene 
frequency is higher in the selected West Midlands districts 
than in Trent and that there is significant regional variation 
in the frequency of MCAD deficiency. A lower frequency of 
G985 MCAD mutation has been reported from the west of 
S~ot land .~  
There has been a long-standing interest in MCAD 
deficiency in Sheffield (Trent) and a high index of suspicion 
is to be expected. The rate of diagnosis in the West 
,Midlands is much lower, although using the gene frequency 
I 
deficiency and supporting anecdotal evidence that this is a l 
. 
-from-a. selected area to calculate the expected number of 
cases for the whole region may have introduced some bias. 
Explanations for the apparently missing cases in the West 
-- incidënce-of malaria recorded in the ICilombero vaccine mal. - Midlands could include a lower awareness of MCAD 
rates of malaria morbidity in both the vaccine and placebo 
cohorts, might-have contributed i o  the lower-than-expected 
--- --- Finally,-weagree.with-Trapeand-Rogier thatit is-likely-that deficiency and its presenting features, failure to detect the 
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